The international expert group arrived in Wuhan and the two men tested positive for antibodies
$1.1 billion partnership Sanofi and Biond to develop ILT2 antibody inhibitors
Lilly Alzheimer's antibody therapy reaches the main clinical endpoint of Phase 2
A new type of antibody astration may be expected to treat chronic inflammation, according to a study in the journal Science
Targeted complement signaling pathrapies Innovative antibody therapies are eligible for FDA priority review
New results in the journal Science: PD-1 Antibody "New Partner" - iNK Cell Therapy
New migraine medicine! Lingbei CGRP targeted antibody Vyepti entered the EU review: the first day of effective, 4 times a year intravenous dosing!